Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline CDH1 sequence variants

The variant curation guidelines published in 2015 by the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP) provided the genetics community with a framework to assess variant pathogenicity; however, these rules are not gene specific. Germline pathogenic variants in the CDH1 gene cause hereditary diffuse gastric cancer and lobular breast cancer, a clinically challenging cancer predisposition syndrome that often requires a multidisciplinary team of experts to be properly managed. Given this challenge, the Clinical Genome Resource (ClinGen) Hereditary Cancer Domain prioritized the development of the CDH1 variant curation expert panel (VCEP) to develop and implement rules for CDH1 variant classifications. Here, we describe the CDH1 specifications of the ACMG/AMP guidelines, which were developed and validated after a systematic evaluation of variants obtained from a cohort of clinical laboratory data encompassing ∼827,000 CDH1 sequenced alleles. Comparing previously reported germline variants that were classified using the 2015 ACMG/AMP guidelines to the CDH1 VCEP recommendations resulted in reduced variants of uncertain significance and facilitated resolution of variants with conflicted assertions in ClinVar. The ClinGen CDH1 VCEP recommends the use of these CDH1‐specific guidelines for the assessment and classification of variants identified in this clinically actionable gene.

[1]  L. Biesecker,et al.  The ACMG/AMP reputable source criteria for the interpretation of sequence variants , 2018, Genetics in Medicine.

[2]  R. Karam,et al.  A novel de novo CDH1 germline variant aids in the classification of carboxy-terminal E-cadherin alterations predicted to escape nonsense-mediated mRNA decay , 2018, Cold Spring Harbor molecular case studies.

[3]  Sara B. Willett,et al.  DNA breakpoint assay reveals a majority of gross duplications occur in tandem reducing VUS classifications in breast cancer predisposition genes , 2018, Genetics in Medicine.

[4]  Sitao Wu,et al.  Quantitative Analysis of BRCA1 and BRCA2 Germline Splicing Variants Using a Novel RNA-Massively Parallel Sequencing Assay , 2018, Front. Oncol..

[5]  B. Bonanni,et al.  Hereditary lobular breast cancer with an emphasis on E-cadherin genetic defect , 2018, Journal of Medical Genetics.

[6]  Bruce D. Gelb,et al.  ClinGen’s RASopathy Expert Panel Consensus Methods for Variant Interpretation , 2018, Genetics in Medicine.

[7]  P. Derksen,et al.  Loss of E-Cadherin-Dependent Cell-Cell Adhesion and the Development and Progression of Cancer. , 2018, Cold Spring Harbor Perspectives in Biology.

[8]  Birgit Funke,et al.  Adaptation and validation of the ACMG/AMP variant classification framework for MYH7-associated inherited cardiomyopathies: recommendations by ClinGen’s Inherited Cardiomyopathy Expert Panel , 2018, Genetics in Medicine.

[9]  Ruifeng Lu,et al.  A central role for cadherin signaling in cancer. , 2017, Experimental cell research.

[10]  Y. Saeys,et al.  Evolution and diversity of cadherins and catenins. , 2017, Experimental cell research.

[11]  Julie O. Culver,et al.  Unexpected CDH1 Mutations Identified on Multigene Panels Pose Clinical Management Challenges. , 2017, JCO precision oncology.

[12]  C. Boland,et al.  Historical Perspective on Familial Gastric Cancer , 2017, Cellular and molecular gastroenterology and hepatology.

[13]  Soma Das,et al.  Clinical Laboratories Collaborate to Resolve Differences in Variant Interpretations Submitted to ClinVar , 2017, Genetics in Medicine.

[14]  D. MacArthur,et al.  Using high-resolution variant frequencies to empower clinical genome interpretation , 2016, Genetics in Medicine.

[15]  Laura H. Tang,et al.  CDH1 Missense Variant c.1679C>G (p.T560R) Completely Disrupts Normal Splicing through Creation of a Novel 5’ Splice Site , 2016, PloS one.

[16]  Madhuri Hegde,et al.  Reassessment of Genomic Sequence Variation to Harmonize Interpretation for Personalized Medicine. , 2016, American journal of human genetics.

[17]  James Y. Zou Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.

[18]  R. Sijmons,et al.  ClinGen and Genetic Testing. , 2015, The New England journal of medicine.

[19]  A. Wagner,et al.  Accuracy of Hereditary Diffuse Gastric Cancer Testing Criteria and Outcomes in Patients With a Germline Mutation in CDH1. , 2015, Gastroenterology.

[20]  J. Adams HIV Outbreak in Indiana. , 2015, New England Journal of Medicine.

[21]  Heidi L Rehm,et al.  ClinGen--the Clinical Genome Resource. , 2015, The New England journal of medicine.

[22]  R. van Hillegersberg,et al.  Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers , 2015, Journal of Medical Genetics.

[23]  Emily K. Tsang,et al.  Effect of predicted protein-truncating genetic variants on the human transcriptome , 2015, Science.

[24]  B. Fernandez,et al.  Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond. , 2015, JAMA oncology.

[25]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[26]  R. Seruca,et al.  Familial gastric cancer: genetic susceptibility, pathology, and implications for management. , 2015, The Lancet. Oncology.

[27]  T. Pesaran,et al.  ClinGen and Genetic Testing. , 2015, The New England journal of medicine.

[28]  R. Seruca,et al.  Hereditary diffuse gastric cancer - pathophysiology and clinical management. , 2014, Best practice & research. Clinical gastroenterology.

[29]  Tina Pesaran,et al.  Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients , 2014, Genetics in Medicine.

[30]  H. Sugimura,et al.  Early-onset diffuse gastric cancer associated with a de novo large genomic deletion of CDH1 gene , 2013, Gastric Cancer.

[31]  F. Roviello,et al.  E-cadherin germline missense mutations in diffuse gastric cancer , 2013 .

[32]  M. Shah,et al.  Gastric cancer epidemiology and risk factors , 2013, Journal of surgical oncology.

[33]  M. Ligtenberg,et al.  Clinical utility gene card for: Hereditary diffuse gastric cancer (HDGC) , 2013, European Journal of Human Genetics.

[34]  R. Seruca,et al.  The importance of E-cadherin binding partners to evaluate the pathogenicity of E-cadherin missense mutations associated to HDGC , 2012, European Journal of Human Genetics.

[35]  M. Shah,et al.  De novo CDH1 mutation in a family presenting with early‐onset diffuse gastric cancer , 2012, Clinical genetics.

[36]  L. Serrano,et al.  E-Cadherin Destabilization Accounts for the Pathogenicity of Missense Mutations in Hereditary Diffuse Gastric Cancer , 2012, PloS one.

[37]  R. Seruca,et al.  Hereditary gastric cancer. , 2009, Best practice & research. Clinical gastroenterology.

[38]  F. van Roy,et al.  Endoplasmic reticulum quality control: a new mechanism of E-cadherin regulation and its implication in cancer. , 2008, Human molecular genetics.

[39]  A. Spurdle,et al.  Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results , 2008, Human mutation.

[40]  D. Huntsman,et al.  The NMD mRNA surveillance pathway downregulates aberrant E-cadherin transcripts in gastric cancer cells and in CDH1 mutation carriers , 2008, Oncogene.

[41]  B. Fernandez,et al.  Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. , 2007, JAMA.

[42]  R. Seruca,et al.  A model to infer the pathogenic significance of CDH1 germline missense variants , 2006, Journal of Molecular Medicine.

[43]  M. Inoue,et al.  Epidemiology of gastric cancer in Japan , 2005, Postgraduate Medical Journal.

[44]  M Vekemans,et al.  Cleft lip/palate and CDH1/E-cadherin mutations in families with hereditary diffuse gastric cancer , 2005, Journal of Medical Genetics.

[45]  M. Hentze,et al.  Nonsense-mediated decay approaches the clinic , 2004, Nature Genetics.

[46]  C. Caldas,et al.  Clinical implications of E-cadherin associated hereditary diffuse gastric cancer , 2004, Gut.

[47]  D. Huntsman,et al.  E-cadherin germline missense mutations and cell phenotype: evidence for the independence of cell invasion on the motile capabilities of the cells. , 2003, Human molecular genetics.

[48]  J. Yokota,et al.  The intracellular E-cadherin germline mutation V832 M lacks the ability to mediate cell–cell adhesion and to suppress invasion , 2003, Oncogene.

[49]  B. Anderson,et al.  Trends in incidence rates of invasive lobular and ductal breast carcinoma. , 2003, JAMA.

[50]  Carla Oliveira,et al.  Identification of CDH1 germline missense mutations associated with functional inactivation of the E-cadherin protein in young gastric cancer probands. , 2003, Human molecular genetics.

[51]  D. Longo,et al.  Truncation of the extracellular region abrogrates cell contact but retains the growth-suppressive activity of E-cadherin. , 2000, Cancer research.

[52]  H. Höfler,et al.  Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. , 1999, The American journal of pathology.

[53]  Anthony E. Reeve,et al.  E-cadherin germline mutations in familial gastric cancer , 1998, Nature.

[54]  M. Vijver,et al.  E‐cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. , 1995, The EMBO journal.

[55]  D. Riethmacher,et al.  A targeted mutation in the mouse E-cadherin gene results in defective preimplantation development. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[56]  M. Takeichi,et al.  Cadherin cell adhesion receptors as a morphogenetic regulator. , 1991, Science.